{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126244","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.933938+00:00","generated_at":"2026-05-15T08:51:11.622542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spero posts Q4 net income $31.5M; tebipenem HBr PDUFA set for June 18, 2026","bullets":["Q4 2025 net income $31.5M (vs $20.9M loss); diluted EPS $0.53.","Full year 2025 net income $8.6M (vs $68.6M loss); diluted EPS $0.15.","Total revenue Q4 $41.3M (vs $15.0M); full year $66.8M (vs $48.0M).","Tebipenem HBr NDA resubmitted; FDA PDUFA date June 18, 2026, per partner GSK.","Cash $40.3M sufficient into 2028; received $25M milestone from GSK in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126244","json":"https://secwatch.observer/filing/0001193125-26-126244.json","markdown":"https://secwatch.observer/filing/0001193125-26-126244.md","text":"https://secwatch.observer/filing/0001193125-26-126244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/0001193125-26-126244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/d107475d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:51:11.622542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1720df31bc278ac88580e1fb742025dd90e56600","claim":"Spero Therapeutics, Inc. reported the year ended December 31, 2025 results: revenue $66.8 million, net income $8.6 million, EPS $0.15.","evidence_excerpt":"fourth quarter of 2025 was primarily due to an increase in collaboration revenue from our agreements with GSK and Pfizer. Total revenue for the year ended December 31, 2025, was $66.8 million, compared to $48.0 million for the year ended December 31, 2024. The revenue increase for the year was primarily due to the aforementioned collaboration revenue related to our","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/0001193125-26-126244-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$66.8 million"},{"label":"Net income","value":"$8.6 million"},{"label":"EPS","value":"$0.15"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8a6742ccd55c60c50f9a2f12fc587c6a1148db31","claim":"Spero Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $41.3 million, net income $31.5 million, EPS $0.53.","evidence_excerpt":"diluted net gain per share of common stock of $0.15 and a diluted net loss per share of common stock of $(1.27), respectively. • Total revenue for the fourth quarter of 2025 was $41.3 million, compared to total revenue of $15.0 million for the fourth quarter of 2024. The revenue increase for the fourth quarter of 2025 was primarily due to an increase in collaboration","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/0001193125-26-126244-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$41.3 million"},{"label":"Net income","value":"$31.5 million"},{"label":"EPS","value":"$0.53"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}